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late loss at 9 months. However, we did not ﬁnd increase of death or MI
in contrast to the previous study, although sample size was small.
Considering early re-endothelialization and no residual polymer of
DEB-BMS strategy, we think that it could be a feasible alternative
treatment option of de novo coronary artery lesions.
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BACKGROUND It remains unclear whether there are differences in
the safety and efﬁcacy outcomes between Cobalt Chronium (CoCr-
EES) and Platinum Chronium everolimus-eluting stents (PtCr-EES).
METHODS From the Interventional Cardiology Research In-Coopera-
tion Society-Drug-Eluting Stents Registry, we identiﬁed 6065
consecutive patients who received CoCr-EES (3080 patients) and PtCr-
EES (2985 patients). We compared major adverse cardiac events
(MACE) which was deﬁned using a composite measure consisting of
death, nonfatal myocardial infarction, or target vessel revasculariza-
tion (TVR) with the use of propensity-score matching in the overall
cohort according to type of stents.
RESULTS At 2-years of clinical follow-up, the 2 study groups (n¼2510
for each propensity matched group) did not differ signiﬁcantly in
crude risk of the MACE (12.0% for CoCr-EES versus 11.6% for PtCr-EES;
HR,0.954; 95% CI, 0.81 – 1.13, p¼0.581).There was also no differences
between the stent groups in the risks of the individual component of
death (HR, 1.083; 95% CI, 0.786 – 1.492, p¼0.624), MI (HR, 0.972; 95%
CI, 0.770 –1.228, p¼0.812), and TVR (HR, 0.798;95% CI, 0.598 – 1.065,
p¼0.125). The risk of cerebrovascular event (HR, 0.914; 95% CI, 0.566 –
1.477, p¼0.714) and deﬁnite stent thrombosis (HR, 1.000; 95% CI,
0.290 – 3.454, p¼1.000) were also similar between the two groups.
CONCLUSION The use of CoCr-EES and PtCr-EES showed similar rates
of safety and efﬁcacy outcomes with regard to death, MI, stent
thrombosis and TVR.TCTAP A-061
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BACKGROUND There are limited data regarding the clinical outcomes
of very long stent implantations, particularly the use of second gen-
eration drug-eluting stents (DES).
METHODS From the IRIS-DES Registry, we identiﬁed 406 patients
who were treated for coronary stenosis using  60 mm of overlapping
drug-eluting stents. Of these, 269 and 137 patients were treated using
cobalt chromium everolimus eluting stent (CoCr-EES) and platinum
chromium everolimus-eluting stents (PtCr-EES), respectively. Major
adverse cardiac events (MACE) were deﬁned using a composite mea-
sure consisting of death, myocardial infarction (MI; periprocedural or
spontaneous), or target vessel revascularization (TVR).
RESULTS Per target lesion, the average stent number was 2.7  0.7
and the average stent length was 76.3  14.8 mm. On 2-year clinical
follow-up, the rate of MACE, death, spontaneous MI, TVR, and stent
thrombosis (deﬁnite or probable stent thrombosis) were 31.8%, 4.4%,
2.0%, 7.1%, and 0.5%, respectively. Although 88patients (21.2%) suf-
fered from periprocedural MI, this was not independently associated
with death, spontaneous MI, or TVR (hazard ratio [HR], 1.097; 95%
conﬁdence interval [CI] 0.58–2.08, p¼ 0.775). In addition, there were
no statistical differences between CoCr-EES and PtCr-EES implanta-
tion in terms of the adjusted risks of MACE (HR, 1.223;95% CI 0.82–
1.82, p ¼ 0.321) as well as its individual components (death; HR, 0.846;
95% CI 0.311–2.305, p ¼ 0.744, MI; HR, 1.101; 95% CI 0.686-1.768, p ¼
0.690, TVR; HR, 1.854; 95% CI 0.895–3.841, p ¼ 0.097).
CONCLUSION When treating diffuse coronary stenosis, multiple
overlapping stent implantations using second generation DES appear
to be equally safe and effective. Although periprocedural MI
frequently occurred, it was not associated with an increase in long-
term adverse clinical outcomes.
